Palvella Therapeutics, Inc.
PVLA
$120.57
-$5.22-4.15%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 17.49M | 15.76M | 13.40M | 11.63M | 8.97M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 45.59M | 38.60M | 31.66M | 26.55M | 20.21M |
| Operating Income | -45.59M | -38.60M | -31.66M | -26.55M | -20.21M |
| Income Before Tax | -49.30M | -41.72M | -32.95M | -28.38M | -23.08M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -49.30 | -41.72 | -32.95 | -28.38 | -23.08 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -49.30M | -41.72M | -32.95M | -28.38M | -23.08M |
| EBIT | -45.59M | -38.60M | -31.66M | -26.55M | -20.21M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -4.16 | -3.70 | -3.56 | -6.47 | -8.08 |
| Normalized Basic EPS | -2.60 | -2.31 | -2.62 | -4.17 | -5.11 |
| EPS Diluted | -4.16 | -3.70 | -3.56 | -6.47 | -8.08 |
| Normalized Diluted EPS | -2.60 | -2.31 | -2.62 | -4.17 | -5.11 |
| Average Basic Shares Outstanding | 47.08M | 45.00M | 36.72M | 27.43M | 18.15M |
| Average Diluted Shares Outstanding | 47.08M | 45.00M | 36.72M | 27.43M | 18.15M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |